Ramalingam Bethunaickan1, Celine C Berthier2, Weijia Zhang3, Ridvan Eksi1, Hong-Dong Li4, Yuanfang Guan4, Matthias Kretzler2, Anne Davidson1. 1. Center for Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, New York, NY 11030. 2. Department of Internal Medicine, Nephrology, University of Michigan, Ann Arbor, MI 48109. 3. Department of Medicine, Mount Sinai Medical Center, New York, NY 10029. 4. Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109.
Abstract
OBJECTIVE: To elucidate the molecular mechanisms involved in renal inflammation during the progression, remission, and relapse of nephritis in murine lupus models using transcriptome analysis. METHODS: Kidneys from (NZB × NZW)F1 (NZB/NZW) and NZM2410 mice were harvested at intervals during the disease course or after remission induction. Genome-wide expression profiles were obtained from microarray analysis of perfused kidneys. Real-time polymerase chain reaction (PCR) analysis for selected genes was used to validate the microarray data. Comparisons between groups using SAM, and unbiased analysis of the entire data set using singular value decomposition and self-organizing maps were performed. RESULTS: Few changes in the renal molecular profile were detected in prenephritic kidneys, but a significant shift in gene expression, reflecting inflammatory cell infiltration and complement activation, occurred at proteinuria onset. Subsequent changes in gene expression predominantly affected mitochondrial dysfunction and metabolic stress pathways. Endothelial cell activation, tissue remodeling, and tubular damage were the major pathways associated with loss of renal function. Remission induction reversed most, but not all, of the inflammatory changes, and progression toward relapse was associated with recurrence of inflammation, mitochondrial dysfunction, and metabolic stress signatures. CONCLUSION: Immune cell infiltration and activation is associated with proteinuria onset and is reversed by immunosuppressive therapy, but disease progression is associated with renal hypoxia and metabolic stress. Optimal therapy for lupus nephritis may therefore need to target both immune and nonimmune disease mechanisms. In addition, the overlap of a substantial subset of molecular markers with those expressed in the kidneys of lupus patients suggests potential new biomarkers and therapeutic targets.
OBJECTIVE: To elucidate the molecular mechanisms involved in renal inflammation during the progression, remission, and relapse of nephritis in murine lupus models using transcriptome analysis. METHODS: Kidneys from (NZB × NZW)F1 (NZB/NZW) and NZM2410 mice were harvested at intervals during the disease course or after remission induction. Genome-wide expression profiles were obtained from microarray analysis of perfused kidneys. Real-time polymerase chain reaction (PCR) analysis for selected genes was used to validate the microarray data. Comparisons between groups using SAM, and unbiased analysis of the entire data set using singular value decomposition and self-organizing maps were performed. RESULTS: Few changes in the renal molecular profile were detected in prenephritic kidneys, but a significant shift in gene expression, reflecting inflammatory cell infiltration and complement activation, occurred at proteinuria onset. Subsequent changes in gene expression predominantly affected mitochondrial dysfunction and metabolic stress pathways. Endothelial cell activation, tissue remodeling, and tubular damage were the major pathways associated with loss of renal function. Remission induction reversed most, but not all, of the inflammatory changes, and progression toward relapse was associated with recurrence of inflammation, mitochondrial dysfunction, and metabolic stress signatures. CONCLUSION: Immune cell infiltration and activation is associated with proteinuria onset and is reversed by immunosuppressive therapy, but disease progression is associated with renal hypoxia and metabolic stress. Optimal therapy for lupus nephritis may therefore need to target both immune and nonimmune disease mechanisms. In addition, the overlap of a substantial subset of molecular markers with those expressed in the kidneys of lupuspatients suggests potential new biomarkers and therapeutic targets.
Authors: P Tamayo; D Slonim; J Mesirov; Q Zhu; S Kitareewan; E Dmitrovsky; E S Lander; T R Golub Journal: Proc Natl Acad Sci U S A Date: 1999-03-16 Impact factor: 11.205
Authors: Chaim O Jacob; Luminita Pricop; Chaim Putterman; Michael N Koss; Yi Liu; Maria Kollaros; Sarah A Bixler; Christine M Ambrose; Martin L Scott; William Stohl Journal: J Immunol Date: 2006-08-15 Impact factor: 5.422
Authors: Brad H Rovin; Huijuan Song; Dan J Birmingham; Lee A Hebert; Chack Yung Yu; Haikady N Nagaraja Journal: J Am Soc Nephrol Date: 2004-12-15 Impact factor: 10.121
Authors: Lena Schiffer; Jayashree Sinha; Xiaobo Wang; Weiqing Huang; Gero von Gersdorff; Mario Schiffer; Michael P Madaio; Anne Davidson; Gero Von Gonsdorff Journal: J Immunol Date: 2003-07-01 Impact factor: 5.422
Authors: D Oleksyn; J Zhao; A Vosoughi; J C Zhao; R Misra; A P Pentland; D Ryan; J Anolik; C Ritchlin; J Looney; A P Anandarajah; G Schwartz; L M Calvi; M Georger; C Mohan; I Sanz; L Chen Journal: Immunol Lett Date: 2017-03-06 Impact factor: 3.685
Authors: Samir V Parikh; Ana Malvar; Huijuan Song; Valeria Alberton; Bruno Lococo; Jay Vance; Jianying Zhang; Lianbo Yu; Dan Birmingham; Brad H Rovin Journal: Transl Res Date: 2016-11-01 Impact factor: 7.012